These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34134802)

  • 1. Methamphetamine use and psychotic symptoms: findings from a New Zealand longitudinal birth cohort.
    Boden JM; Foulds JA; Newton-Howes G; McKetin R
    Psychol Med; 2023 Feb; 53(3):987-994. PubMed ID: 34134802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study.
    McKetin R; Lubman DI; Baker AL; Dawe S; Ali RL
    JAMA Psychiatry; 2013 Mar; 70(3):319-24. PubMed ID: 23303471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direction of the relationship between methamphetamine use and positive psychotic symptoms in regular methamphetamine users: evidence from a prospective cohort study.
    Hides L; Chan G; Dawe S; McKetin R; Kavanagh DJ; Young RM; Teesson M; Saunders JB
    Br J Psychiatry; 2021 Jul; 219(1):361-367. PubMed ID: 31950892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How does a family history of psychosis influence the risk of methamphetamine-related psychotic symptoms: Evidence from longitudinal panel data.
    McKetin R; Clare PJ; Castle D; Turner A; Kelly PJ; Lubman DI; Arunogiri S; Manning V; Berk M
    Addiction; 2023 Oct; 118(10):1975-1983. PubMed ID: 37157055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between the duration of methamphetamine use and psychotic symptoms: A two-year prospective cohort study.
    Ma J; Li XD; Wang TY; Li SX; Meng SQ; Blow FC; Ilgen M; Degenhardt L; Lappin J; Wu P; Shi J; Bao YP; Lu L
    Drug Alcohol Depend; 2018 Jun; 187():363-369. PubMed ID: 29715654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of substance use, psychosis, and mortality among people living in precarious housing or homelessness: A longitudinal, community-based study in Vancouver, Canada.
    Jones AA; Gicas KM; Seyedin S; Willi TS; Leonova O; Vila-Rodriguez F; Procyshyn RM; Smith GN; Schmitt TA; Vertinsky AT; Buchanan T; Rauscher A; Lang DJ; MacEwan GW; Lima VD; Montaner JSG; Panenka WJ; Barr AM; Thornton AE; Honer WG
    PLoS Med; 2020 Jul; 17(7):e1003172. PubMed ID: 32628679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does methamphetamine use increase violent behaviour? Evidence from a prospective longitudinal study.
    McKetin R; Lubman DI; Najman JM; Dawe S; Butterworth P; Baker AL
    Addiction; 2014 May; 109(5):798-806. PubMed ID: 24400972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review of risk factors for methamphetamine-associated psychosis.
    Arunogiri S; Foulds JA; McKetin R; Lubman DI
    Aust N Z J Psychiatry; 2018 Jun; 52(6):514-529. PubMed ID: 29338289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First psychotic episode risk markers for primary psychosis amongst people who use methamphetamine.
    McKetin R; Hides L; Kavanagh DJ; Saunders JB; Dawe S
    Schizophr Res; 2018 Sep; 199():456-457. PubMed ID: 29680188
    [No Abstract]   [Full Text] [Related]  

  • 10. Correlates of transient versus persistent psychotic symptoms among dependent methamphetamine users.
    McKetin R; Gardner J; Baker AL; Dawe S; Ali R; Voce A; Leach LS; Lubman DI
    Psychiatry Res; 2016 Apr; 238():166-171. PubMed ID: 27086229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in the symptom profile of methamphetamine-related psychosis and primary psychotic disorders.
    McKetin R; Baker AL; Dawe S; Voce A; Lubman DI
    Psychiatry Res; 2017 May; 251():349-354. PubMed ID: 28282630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methamphetamine use and violence: Findings from a longitudinal birth cohort.
    Foulds JA; Boden JM; McKetin R; Newton-Howes G
    Drug Alcohol Depend; 2020 Feb; 207():107826. PubMed ID: 31927159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remission of persistent methamphetamine-induced psychosis after cariprazine therapy: presentation of a case report.
    Ricci V; Di Salvo G; Maina G
    J Addict Dis; 2022; 40(1):145-148. PubMed ID: 34180372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk and associated factors of methamphetamine psychosis in methamphetamine-dependent patients in Malaysia.
    Sulaiman AH; Said MA; Habil MH; Rashid R; Siddiq A; Guan NC; Midin M; Nik Jaafar NR; Sidi H; Das S
    Compr Psychiatry; 2014 Jan; 55 Suppl 1():S89-94. PubMed ID: 23433219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The profile of psychiatric symptoms exacerbated by methamphetamine use.
    McKetin R; Dawe S; Burns RA; Hides L; Kavanagh DJ; Teesson M; McD Young R; Voce A; Saunders JB
    Drug Alcohol Depend; 2016 Apr; 161():104-9. PubMed ID: 26874915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence of psychotic symptoms among methamphetamine users.
    McKetin R; McLaren J; Lubman DI; Hides L
    Addiction; 2006 Oct; 101(10):1473-8. PubMed ID: 16968349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hospital separations for cannabis- and methamphetamine-related psychotic episodes in Australia.
    Degenhardt L; Roxburgh A; McKetin R
    Med J Aust; 2007 Apr; 186(7):342-5. PubMed ID: 17407429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased prevalence of self-reported psychotic illness predicted by crystal methamphetamine use: Evidence from a high-risk population.
    Lappin JM; Roxburgh A; Kaye S; Chalmers J; Sara G; Dobbins T; Burns L; Farrell M
    Int J Drug Policy; 2016 Dec; 38():16-20. PubMed ID: 27842249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse childhood experiences and interaction with methamphetamine use frequency in the risk of methamphetamine-associated psychosis.
    Ding Y; Lin H; Zhou L; Yan H; He N
    Drug Alcohol Depend; 2014 Sep; 142():295-300. PubMed ID: 25064022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methamphetamine Use and Antipsychotic-related Extrapyramidal Side-effects in Patients with Psychotic Disorders.
    Temmingh HS; van den Brink W; Howells F; Sibeko G; Stein DJ
    J Dual Diagn; 2020; 16(2):208-217. PubMed ID: 31984872
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.